Vivoryon Therapeutics N.V. (0R3M.L)

EUR 1.77

(-0.56%)

Total Liabilities Summary of Vivoryon Therapeutics N.V.

Vivoryon Therapeutics N.V.'s latest annual total liabilities in 2023 was 4.54 Million EUR , down -6.67% from previous year.
Vivoryon Therapeutics N.V.'s latest quarterly total liabilities in 2024 Q2 was 3.01 Million EUR , down 0.0% from previous quarter.
Vivoryon Therapeutics N.V. reported annual total liabilities of 4.87 Million EUR in 2022, down -38.82% from previous year.
Vivoryon Therapeutics N.V. reported annual total liabilities of 7.96 Million EUR in 2021, up 125.58% from previous year.
Vivoryon Therapeutics N.V. reported quarterly total liabilities of 4.54 Million EUR for 2023 Q4, down 0.0% from previous quarter.
Vivoryon Therapeutics N.V. reported quarterly total liabilities of 3.82 Million EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Total Liabilities Chart of Vivoryon Therapeutics N.V. (2023 - 2010)

Historical Annual Total Liabilities of Vivoryon Therapeutics N.V. (2023 - 2010)

Year	Total Liabilities	Total Liabilities Growth
2023	4.54 Million EUR	-6.67%
2022	4.87 Million EUR	-38.82%
2021	7.96 Million EUR	125.58%
2020	3.53 Million EUR	10.45%
2019	3.19 Million EUR	113313.77%
2018	2818.00 EUR	53.24%
2017	1839.00 EUR	-69.3%
2016	5990.00 EUR	4.48%
2015	5733.00 EUR	4.07%
2014	5509.00 EUR	-99.95%
2013	10.59 Million EUR	128.41%
2012	4.64 Million EUR	11.86%
2011	4.14 Million EUR	11.3%
2010	3.72 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	3.01 Million EUR	0.0%
2023 Q4	4.54 Million EUR	0.0%
2023 Q2	3.82 Million EUR	0.0%
2023 FY	4.54 Million EUR	-6.67%
2022 Q2	6.5 Million EUR	0.0%
2022 FY	4.87 Million EUR	-38.82%
2022 Q4	4.87 Million EUR	0.0%
2021 FY	7.96 Million EUR	125.58%
2021 Q2	7.57 Million EUR	0.0%
2021 Q4	7.96 Million EUR	0.0%
2020 Q4	3.53 Million EUR	0.0%
2020 FY	3.53 Million EUR	10.45%
2020 Q2	2.82 Million EUR	0.0%
2019 FY	3.19 Million EUR	113313.77%
2019 Q4	3.19 Million EUR	0.0%
2019 Q2	3.63 Million EUR	0.0%
2018 FY	2818.00 EUR	53.24%
2018 Q2	2321.00 EUR	0.0%
2018 Q4	2818.00 EUR	0.0%
2017 Q2	2760.00 EUR	0.0%
2017 FY	1839.00 EUR	-69.3%
2017 Q4	1839.00 EUR	0.0%
2016 Q4	5990.00 EUR	0.0%
2016 Q2	5275.00 EUR	0.0%
2016 FY	5990.00 EUR	4.48%
2015 Q2	5223.00 EUR	0.0%
2015 Q4	5733.00 EUR	0.0%
2015 FY	5733.00 EUR	4.07%
2014 Q2	14.65 Thousand EUR	0.0%
2014 Q4	5509.00 EUR	0.0%
2014 FY	5509.00 EUR	-99.95%
2013 Q4	10.59 Million EUR	0.0%
2013 FY	10.59 Million EUR	128.41%
2012 FY	4.64 Million EUR	11.86%
2011 FY	4.14 Million EUR	11.3%
2010 FY	3.72 Million EUR	0.0%

Peer Total Liabilities Comparison of Vivoryon Therapeutics N.V.

Name	Total Liabilities	Total Liabilities Difference
Boiron SA	198.7 Million EUR	97.712%
Laboratorios Farmaceuticos Rovi, S.A.	256.39 Million EUR	98.227%
Vetoquinol SA	165.12 Million EUR	97.246%
Valneva SE	341.14 Million EUR	98.667%
AB Science S.A.	46.5 Million EUR	90.223%
Nanobiotix S.A.	95.74 Million EUR	95.251%
PHAXIAM Therapeutics S.A.	25.69 Million EUR	82.304%
BioSenic S.A.	32.26 Million EUR	85.907%
ABIVAX Société Anonyme	131.05 Million EUR	96.53%
Formycon AG	387.61 Million EUR	98.827%